FDA clears Propeller Health sensor for use with AstraZeneca's Symbicort inhaler
The digital respiratory health company says this deal and clearance now give it access to 90% of the U.S. asthma and COPD market. (Source: mobihealthnews)
Source: mobihealthnews - May 26, 2020 Category: Information Technology Source Type: news
EMA Panel Backs Budesonide/Formoterol Hybrid for Asthma, COPD EMA Panel Backs Budesonide/Formoterol Hybrid for Asthma, COPD
The CHMP has endorsed the hybrid medicine Budesonide/Formoterol Teva Pharma B.V., a duplicate of DuoResp Spiromax, for adults with asthma and chronic obstructive pulmonary disease.International Approvals (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - January 31, 2020 Category: Allergy & Immunology Tags: Pulmonary Medicine News Alert Source Type: news
Highmark ’s Outcomes-Based Contract for SYMBICORT ® Improves...
Highmark announced that its outcomes-based contract with AstraZeneca for the respiratory medicine SYMBICORT® demonstrated positive results in improving patient outcomes for the treatment of...(PRWeb October 28, 2019)Read the full story at https://www.prweb.com/releases/highmarks_outcomes_based_contract_for_symbicort_improves_patient_outcomes_for_asthma_copd/prweb16665934.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 28, 2019 Category: Pharmaceuticals Source Type: news
budesonide/formoterol hfa inhaler (Symbicort)
Title: budesonide/formoterol hfa inhaler (Symbicort)Category: MedicationsCreated: 3/2/2005 12:00:00 AMLast Editorial Review: 8/20/2019 12:00:00 AM (Source: MedicineNet Asthma General)
Source: MedicineNet Asthma General - August 20, 2019 Category: Respiratory Medicine Source Type: news
Breztri Aerosphere (PT010) approved in Japan for patients with chronic obstructive pulmonary disease
AstraZeneca announced that Breztri Aerosphere (budesonide/glycopyrronium/ formoterol fumarate), formerly PT010, has been approved in Japan as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD). This is the first global regulatory approval for Breztri Aerosphere and is the first approval by (Source: World Pharma News)
Source: World Pharma News - June 20, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
New data show Symbicort reduces attacks in mild asthma when used as an anti-inflammatory reliever
New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol) as a potential anti-inflammatory reliever in mild asthma.(1) These results are published in the New England Journal of Medicine and are being presented at the American Thoracic Society 2019 International Conference.(1) (Source: World Pharma News)
Source: World Pharma News - May 22, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Mometasone, Tiotropium Do Not Top Placebo in Mild Asthma
MONDAY, May 20, 2019 -- For patients with mild asthma with a low sputum eosinophil level, outcomes do not differ significantly for mometasone or tiotropium versus placebo; and budesonide-formoterol is superior to albuterol for prevention of asthma... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 20, 2019 Category: Pharmaceuticals Source Type: news
How Digital Health Technologies Could Make a Difference
Digital technologies are already changing healthcare. Adherium’s Hailie sensor, for instance, which transforms a traditional inhaler into a smart device, is already reportedly demonstrating reductions in emergency hospital visits. Mark Jones, vice president of R&D for Adherium, will share the story behind Hailie at BIOMEDevice San Jose’s Digital Health Product Spotlight on December 6. He’ll be joined by other digital technology trailblazers Angela McIntyre, executive director of eWear (Stanford Wearable Electronics Initiative); Chalisa Prarasri, CEO & co-founder...
Source: MDDI - November 15, 2018 Category: Medical Devices Authors: Daphne Allen Tags: BIOMEDevice San Jose Digital Health Source Type: news
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
AstraZeneca today announced publication of results from the KRONOS Phase III trial which evaluated the efficacy and safety of triple combination therapy PT010 (budesonide/ glycopyrronium/formoterol fumarate) versus dual combination therapies Bevespi Aerosphere (glycopyrronium/formoterol fumarate), Symbicort Turbuhaler (budesonide/formoterol fumarate) and PT009 (budesonide/formoterol fumarate) in patients with (Source: World Pharma News)
Source: World Pharma News - September 17, 2018 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
Could a Direct-to-Consumer Sensor Improve Adherence?
In March, Adherium received 510(k) clearance from FDA for over-the-counter (OTC) sales of its Smartinhaler sensor for AstraZeneca’s Symbicort aerosol asthma inhaler and is now preparing to sell its sensor-based solution directly to patients. The sensor, which has since been rebranded as Hailie, fits around a patient’s inhaler “a bit like a jacket,” explains CEO Arik Anderson. The Bluetooth-enabled sensor can be integrated into any inhaler and pairs with an app on a smartphone (see below right) to provide “coaching support” such as dosing reminders and alerts, he told MD+DI. It can communicate with patients as ...
Source: MDDI - July 6, 2018 Category: Medical Devices Authors: Daphne Allen Tags: Digital Health Source Type: news
Budesonide-Formoterol Used As Needed Beneficial in Mild Asthma
THURSDAY, May 17, 2018 -- Inhaled combined budesonide-formoterol used as needed is beneficial for mild asthma, according to two studies published in the May 17 issue of the New England Journal of Medicine.
Paul M. O ' Byrne, from McMaster University... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 17, 2018 Category: Pharmaceuticals Source Type: news
AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug
Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease.
Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware.
Get the full story at our sister site, Drug Delivery Business News.
The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 17, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat AstraZeneca plc Source Type: news
FDA clears Adherium ’ s inhaler sensor for OTC sales
The FDA gave Adherium (ASK:ADR) the go-ahead to launch over-the-counter sales of its Smartinhaler sensor for AstraZeneca‘s (NYSE:AZN) Symbicort asthma inhaler, the company touted last week.
Adherium’s product installs directly onto a patient’s inhaler to monitor and boost medication adherence. The device records the time and date that a patient uses their inhaler and transmits the data to an app on the user’s phone or tablet. This feature allows users and physicians to track a patient’s medication usage patterns, according to Adherium.
Get the full story at our sister site, Drug Delivery Business ...
Source: Mass Device - April 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: 510(k) Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Respiratory Wall Street Beat Adherium Limited AstraZeneca plc Source Type: news
Adherium receives OTC clearance for AstraZeneca's Symbicort inhaler
Smart inhaler company Adherium announced last week that it has received 510(k) clearance for over-the-counter sales of its inhaler monitoring device for AstraZeneca ’s Symbicort aerosol inhaler, called the SmartTouch for Symbicort. (Source: mobihealthnews)
Source: mobihealthnews - April 2, 2018 Category: Information Technology Source Type: news
Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech
Adherium Ltd. (ASK:ADR), which sells a smart inhaler technology in Europe and Australia, is reportedly looking to jump into the direct-to-consumer U.S. market in the first half of this year.
The New Zealand-based company has a deal with AstraZeneca (NYSE:AZN) to combine its Smartinhaler monitoring device with the Symbicort inhaler, but CEO Arik Anderson told MobiHealthNews that he is also looking for other opportunities to penetrate the U.S. market.
Get the full story at our sister site, Drug Delivery Business News.
The post Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech appear...
Source: Mass Device - January 25, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat Adherium Limited AstraZeneca plc Source Type: news
